Eli Lilly’s research collaboration with Peptron on the SmartDepot sustained-release microsphere platform, which uses ultrasonic spray drying for long-acting peptide formulations, remains limited to non-commercial feasibility studies and joint evaluation of once-monthly dosing for GLP-1 candidates. Recent June and July 2026 updates confirm expanded research scope and internal verification of SmartDepot applicability, yet no formal commercial licensing, technology transfer, or binding agreement has been announced. Lilly has already executed a separate deal with Camurus for a competing FluidCrystal platform, adding competitive pressure, while the roughly seven-week window to the October 7 resolution date leaves little room for deal negotiation, regulatory review, or public disclosure. Traders therefore assign an 84.5% implied probability to “No,” reflecting the gap between ongoing technical assessment and the specific commercial milestone required for market resolution.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado16% probabilidad
$11,264 Vol.
$11,264 Vol.
6 oct 2026
16% probabilidad
$11,264 Vol.
$11,264 Vol.
6 oct 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s research collaboration with Peptron on the SmartDepot sustained-release microsphere platform, which uses ultrasonic spray drying for long-acting peptide formulations, remains limited to non-commercial feasibility studies and joint evaluation of once-monthly dosing for GLP-1 candidates. Recent June and July 2026 updates confirm expanded research scope and internal verification of SmartDepot applicability, yet no formal commercial licensing, technology transfer, or binding agreement has been announced. Lilly has already executed a separate deal with Camurus for a competing FluidCrystal platform, adding competitive pressure, while the roughly seven-week window to the October 7 resolution date leaves little room for deal negotiation, regulatory review, or public disclosure. Traders therefore assign an 84.5% implied probability to “No,” reflecting the gap between ongoing technical assessment and the specific commercial milestone required for market resolution.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Mercado abierto: May 5, 2026, 8:02 PM ET
Volumen
$11,264Fecha de finalización
7 oct 2026Mercado abierto
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s research collaboration with Peptron on the SmartDepot sustained-release microsphere platform, which uses ultrasonic spray drying for long-acting peptide formulations, remains limited to non-commercial feasibility studies and joint evaluation of once-monthly dosing for GLP-1 candidates. Recent June and July 2026 updates confirm expanded research scope and internal verification of SmartDepot applicability, yet no formal commercial licensing, technology transfer, or binding agreement has been announced. Lilly has already executed a separate deal with Camurus for a competing FluidCrystal platform, adding competitive pressure, while the roughly seven-week window to the October 7 resolution date leaves little room for deal negotiation, regulatory review, or public disclosure. Traders therefore assign an 84.5% implied probability to “No,” reflecting the gap between ongoing technical assessment and the specific commercial milestone required for market resolution.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volumen
$11,264Fecha de finalización
7 oct 2026Mercado abierto
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s research collaboration with Peptron on the SmartDepot sustained-release microsphere platform, which uses ultrasonic spray drying for long-acting peptide formulations, remains limited to non-commercial feasibility studies and joint evaluation of once-monthly dosing for GLP-1 candidates. Recent June and July 2026 updates confirm expanded research scope and internal verification of SmartDepot applicability, yet no formal commercial licensing, technology transfer, or binding agreement has been announced. Lilly has already executed a separate deal with Camurus for a competing FluidCrystal platform, adding competitive pressure, while the roughly seven-week window to the October 7 resolution date leaves little room for deal negotiation, regulatory review, or public disclosure. Traders therefore assign an 84.5% implied probability to “No,” reflecting the gap between ongoing technical assessment and the specific commercial milestone required for market resolution.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes